Lipocine
LPCN
32 hedge funds and large institutions have $5.56M invested in Lipocine in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 31 → 32 (+1)
0.02% less ownership
Funds ownership: 0.71% → 0.68% (-0.02%)
16% less capital invested
Capital invested by funds: $6.63M → $5.56M (-$1.07M)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
40% less call options, than puts
Call options by funds: $29K | Put options by funds: $48K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$161K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$137K |
| 3 |
BlackRock
New York
|
+$97.2K |
| 4 |
QCMA
Quad Capital Management Advisors
New York
|
+$43.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$34.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$234K |
| 2 |
Mercer Global Advisors
Denver,
Colorado
|
-$76.3K |
| 3 |
SIM
Spark Investment Management
New York
|
-$60.6K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$56.1K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $6K | -$24K | -777 | -82% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $4K | +$3.58K | +116 | New |
|
28
Morgan Stanley
New York
| $3K | -$895 | -29 | -22% |
|
|
BFEC
29
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $3K | – | – | – |
|
|
AG
30
Advisor Group
Phoenix,
Arizona
| $2K | – | – | – |
|
31
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$586 | -19 | -51% |
|
|
MF
32
Manchester Financial
Westlake Village,
California
| $1K | +$895 | +29 | New |
|
33
BNP Paribas Financial Markets
Paris,
France
| $8 | – | – | – |
|
|
34
Acadian Asset Management
Boston,
Massachusetts
| – | -$41K | -1,056 | Closed |
|
35
Two Sigma Investments
New York
| – | -$34K | -860 | Closed |
|
36
Citadel Advisors
Miami,
Florida
| – | -$24K | -609 | Closed |
|
LPCN Hedge Fund Activity: Q2 2019 in Review
32 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2019, worth a combined $5.56M — down 16% from $6.63M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LPCN positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $161K. The largest seller was Ameriprise, cutting an estimated $234K.
- 32 institutional investors held Lipocine (LPCN) as of Q2 2019, up from 31 in Q1 2019.
- Funds reported $5.56M of Lipocine stock for Q2 2019, down 16% quarter-over-quarter.
- 4 funds opened new Lipocine positions in Q2 2019 and 3 closed out, a net change of +1 holder.
- The largest Lipocine buyer in Q2 2019 was Renaissance Technologies, an estimated $161K added.
- The largest Lipocine seller in Q2 2019 was Ameriprise, an estimated $234K sold.
Based on aggregated 13F filings for Q2 2019.